CIM
ALXN

Contravisory Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Contravisory Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,136
Closed -$392K – 286
2021
Q2 		$392K Sell
2,136
-66
-3% -$11.3K 0.12% 117
2021
Q1 		$337K Sell
2,202
-39
-2% -$6.03K 0.11% 111
2020
Q4 		$350K Sell
2,241
-272
-11% -$35K 0.11% 96
2020
Q3 		$288K Hold
2,513
– – 0.1% 120
2020
Q2 		$285K Buy
+2,513
New +$267K 0.1% 108

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Contravisory Investment Management's ALXN Position: Q3 2021 in Review

Contravisory Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,136 shares — an estimated $392K sold.

Contravisory Investment Management first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $392K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Contravisory Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Contravisory Investment Management sold 2,136 Alexion Pharmaceuticals shares in Q3 2021, an estimated $392K.
  • Contravisory Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Contravisory Investment Management's Alexion Pharmaceuticals position peaked at $392K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Contravisory Investment Management's 13F filing for Q3 2021, filed 12 Oct 2021.